Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a plant oil spray tame chronic sinusitis with fewer steroids?

NCT ID NCT07800273

Disease control Sponsor: Liaquat University of Medical & Health Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests whether adding a nasal spray made from pistacia lentiscus oil can help people with chronic rhinosinusitis control their symptoms while using a lower dose of a standard corticosteroid spray. Adults with the condition will be randomly assigned to either the oil spray plus a reduced steroid dose or the full steroid dose alone for 12 weeks. Researchers will measure changes in quality of life, nasal congestion, and runny nose to see if the oil spray works as well as the full steroid treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bactorinol nasal spray (pistacia lentiscus oil) plus a reduced dose of mometasone furoate nasal spray
What this could lead to
If it works, this could offer a way to control chronic rhinosinusitis symptoms with less corticosteroid use, potentially reducing side effects while keeping quality of life.
What could go wrong
This is a small, early-stage trial, so results may not apply broadly. The oil spray might not match the full-dose steroid in controlling symptoms, and nasal irritation or other side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 78 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Patients diagnosed with chronic rhinosinusitis with nasal polyposis (CRSwNP) and without polyposis (CRSsNP) * Clinical indication for treatment with intranasal corticosteroid (mometasone furoate) * Ability to understand and sign informed consent * Willingness to comply with the study protocol and follow-up visits (T0, T12 weeks) Exclusion Criteria: * Neoplastic pathologies of all degrees * Neurological or psychiatric disorders such as to impair adherence to treatment and/or understanding of informed consent forms * Pregnancy and lactation * Chronic drug and/or alcohol use * Immunosuppressed subjects (primary immunodepression, oncological pathology undergoing active chemo/immunotherapy treatment, autoimmune pathology undergoing immunosuppressive treatment) * Allergy, even suspected, to one or more of the excipients of the preparation under study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic rhinosinusitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic rhinosinusitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic rhinosinusitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Armonia Centro Polispecialistico

    Porto Mantovano, Lombardy, 46047, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.